Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy

Praful Ravi, MB BChir, Shaji Kumar, MD, Wilson I Gonsalves, MD, Francis K Buadi, MD, Martha Q. Lacy, MD, Ronald S. Go, MD, Angela Dispenzieri, MD, Prashant Kapoor, MD, John A Lust, MD PhD, David Dingli, MD PhD FRCP, Yi Lin, MD PhD, Stephen J. Russell, MD PhD, Nelson Leung, MD, Morie A. Gertz, MD, Robert A. Kyle, MD, Leif Bergsagel, MD, S. Vincent Rajkumar, MD

Blood (2016) 128 (22): 3251.

https://doi.org/10.1182/blood.V128.22.3251.3251

Published: 2016

Journal Articles

Abnormal Heavy/Light Chain Ratio after Treatment Is a Robust Predictor of Shorter Survival in Patients with IgA Myeloma

Yoshiaki Abe, MD, Yasuhito Suehara, MD, Hiroyuki Takamatsu, MD PhD, Yoshiaki Usui, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kelly Endean, PhD, Kosei Matsue, MD PhD

Blood (2016) 128 (22): 3254.

https://doi.org/10.1182/blood.V128.22.3254.3254

Published: 2016

Journal Articles

Infection Complications in 476 Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide or Bortezomib Combinations

Massimo Offidani, Laura Corvatta, Sara Bringhen, Silvia Gentili, Francesca Gay, Laura Maracci, Mario Boccadoro, Pietro Leoni, Antonio Palumbo

Blood (2015) 126 (23): 5365.

https://doi.org/10.1182/blood.V126.23.5365.5365

Published: 2015

Journal Articles

Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant

Koji Sasaki, MD, Nina Shah, MD, Qaiser Bashir, MD, Chitra M. Hosing, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Simrit Parmar, MD, Jatin J. Shah, MD, Donna Weber, MD, Daniel Weissinger, Sheeba K. Thomas, MD, Robert Z. Orlowski, MD PhD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2015) 126 (23): 3194.

https://doi.org/10.1182/blood.V126.23.3194.3194

Published: 2015

Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study

Blood (2014) 124 (21): 4734.

https://doi.org/10.1182/blood.V124.21.4734.4734

Published: 2014

Journal Articles

Immunoglobulin Heavy/Light Chain Immunoassays for Response Evaluation in Multiple Myeloma: Comparison with Immunofixation, Serum Free Light Chain, and Multicolor Flow- Cytometry

Yasuhito Suehara, MD, Keisuke Seike, MD, Kouta Fukumoto, Manabu Fujisawa, MD, Masafumi Fukaya, MD, Hiroki Sugihara, MD, Masami Takeuchi, MD, Hiroyuki Takamatsu, MD PhD, Kelly Endean, Stephen Harding, PhD, Kosei Matsue, MD PhD

Blood (2014) 124 (21): 3366.

https://doi.org/10.1182/blood.V124.21.3366.3366

Published: 2014

Journal Articles

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Blood (2013) 122 (21): 1866.

https://doi.org/10.1182/blood.V122.21.1866.1866

Published: 2013

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Blood (2013) 122 (21): 1974.

https://doi.org/10.1182/blood.V122.21.1974.1974

Published: 2013

Journal Articles

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

Meletios A. Dimopoulos, MD, Robert Z. Orlowski, M.D., Ph.D, Thierry Facon, MD, Pieter Sonneveld, MD, Ph.D, Kenneth C. Anderson, MD, Meral Beksac, MD, Lotfi Benboubker, MD, Huw Roddie, MBChB, Ph.D, Anna Potamianou, MD, Catherine Couturier, PharmD, Huaibao Feng, Ph.D, Ozlem Ataman, MD, Ph.D, Helgi van de Velde, Paul G. Richardson, MD

Blood (2013) 122 (21): 3177.

https://doi.org/10.1182/blood.V122.21.3177.3177

Published: 2013

Journal Articles

Comparison Of Hevylite™ Assay and Plasma Cell Immunophenotyping For Response Evaluation and Residual Disease Characterisation In IgA Myeloma

Daniela Lakomy, Stephanie Lemaire-Ewing, Cedric Rossi, Jessica Borgeot, Jean-Noël Bastie, Ingrid Lafon, Marc Maynadie, Denis Caillot, MD, Julien Guy

Blood (2013) 122 (21): 5319.

https://doi.org/10.1182/blood.V122.21.5319.5319

Published: 2013

Journal Articles

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

Annamaria Brioli, MD, John P. Campbell, PhD, Martin F Kaiser, MD, Charlotte Pawlyn, MD, Graham H. Jackson, MD, Walter Gregory, PhD, Roger G. Owen, MD, J. Anthony Child, MD, Faith E. Davies, MD, Michele Cavo, MD, Mark T. Drayson, MD PhD, Gareth J. Morgan, MD PhD

Blood (2013) 122 (21): 752.

https://doi.org/10.1182/blood.V122.21.752.752

Published: 2013

Journal Articles

IgA Hevylite® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma

Eileen Mary Boyle, MD, Philip Young, Helene Demarquette, MD, Julie Gay, MD, Houria Debarri, MD, Sarah Bonnet, MD, Charles Herbaux, MD, Remy Dulery, MD, Salomon Manier, MD, Jean-Luc Faucompre, Frederic Combat, MD, Annie Pietrantuono, MD, Brigitte Onraed, Bernadette Hennache, Thierry Facon, MD, Stephen J Harding, MD, PhD, Xavier Leleu, MD, PhD

Blood (2012) 120 (21): 3970.

https://doi.org/10.1182/blood.V120.21.3970.3970

Published: 2012

Journal Articles

Multiple Myeloma Variant with Ascites and Cytoplasmic Crystalline Granules in Plasma Cells

Cesar Rodriguez, MD, Anthony Janckila, Sylvia Potenziani, MD, Vivek R. Sharma, MD, FRCPA

Blood (2011) 118 (21): 5088.

https://doi.org/10.1182/blood.V118.21.5088.5088

Published: 2011

Journal Articles

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Seungsoo Lee, MS, Mitch A. Phelps, PhD, Don M Benson, Jr, MD, PhD, Eric H. Kraut, MD, William J Hicks, MD, Deidre Deam, RN, Amy J Johnson, PhD, Sherif Farag, MD, PhD, FRACP, FRCPA, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD

Blood (2010) 116 (21): 1933.

https://doi.org/10.1182/blood.V116.21.1933.1933

Published: 2010

Journal Articles

The Relationship Between Serum Free Light Chain Levels and Urine Protein in Patients with IgG or IgA Myeloma.

J. Mehta, E. Vickrey, D. Ramadurai, E. Voigt, C. Fitzpatrick, S. Singhal

Blood (2009) 114 (22): 1810.

https://doi.org/10.1182/blood.V114.22.1810.1810

Published: 2009

Journal Articles

Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.

Herve AvetLoiseau, MD, Jean-Luc Harousseau, Philippe Moreau, MD, Claire Mathiot, Thierry Facon, Michel Attal, MD, Arthur Bradwell, FRCP, FRCPath, Stephen Harding, PhD

Blood (2009) 114 (22): 1818.

https://doi.org/10.1182/blood.V114.22.1818.1818

Published: 2009

Journal Articles

Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.

Holger W Auner, Hilda Owiti, Chrissy Giles, Jiri Pavlu, Donald MacDonald, Edward Kanfer, Jane F Apperley, Amin Rahemtulla

Blood (2009) 114 (22): 1781.

https://doi.org/10.1182/blood.V114.22.1781.1781

Published: 2009

Journal Articles

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

Edward Agura, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Nikhil Munshi, MD, Mohamad Hussein, MD, Ramakrishnan V Parameswaran, MD, Stefano Tarantolo, MD, Nancy C Whiting, PharmD, BCOP, Jonathan G Drachman, MD, Jeffrey A Zonder, MD

Blood (2009) 114 (22): 2870.

https://doi.org/10.1182/blood.V114.22.2870.2870

Published: 2009

Journal Articles

The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios

Seema Singhal, Eric Vickrey, Jairam Krishnamurthy, Veerpal Singh, Sharon Allen, Jayesh Mehta

Blood (2009) 114 (1): 38–39.

https://doi.org/10.1182/blood-2009-02-205807

Published: 2009

NARROW

Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy

Abnormal Heavy/Light Chain Ratio after Treatment Is a Robust Predictor of Shorter Survival in Patients with IgA Myeloma

Infection Complications in 476 Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide or Bortezomib Combinations

Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant

Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study

Immunoglobulin Heavy/Light Chain Immunoassays for Response Evaluation in Multiple Myeloma: Comparison with Immunofixation, Serum Free Light Chain, and Multicolor Flow- Cytometry

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

Comparison Of Hevylite™ Assay and Plasma Cell Immunophenotyping For Response Evaluation and Residual Disease Characterisation In IgA Myeloma

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

IgA Hevylite® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma

Multiple Myeloma Variant with Ascites and Cytoplasmic Crystalline Granules in Plasma Cells

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

The Relationship Between Serum Free Light Chain Levels and Urine Protein in Patients with IgG or IgA Myeloma.

Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.

Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only